slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 73,291-73,320
Pages 3,679
Rows per page 30
Component
73,291-73,320 of 110,355
13
The table provides a transparent breakdown of non-GAAP adjustments including equity compensation, revaluation of earnout consideration, and facility start-up costs.Lakeland Bancorp | Results Presentation Deck | 14 slides · Lakeland
Conference presentation Investor relations 1 hit
14
Lakeland Bancorp | Results Presentation Deck | 14 slidesLakeland Bancorp | Results Presentation Deck | 14 slides · Lakeland
Conference presentation Investor relations 1 hit
03
The slide provides a high-level summary of the company's pipeline and financial runway.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations 1 hit
04
Uses a visual icon array to represent the '1 in 4' statistic.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
06
The slide uses a circular flywheel diagram to represent the IP strategy and a horizontal bar chart to illustrate market exclusivity duration.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
08
Uses a brain diagram to map specific therapeutic areas to clinical evidence points.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
09
Uses scientific visualization to illustrate the drug's impact on brain function.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
11
Uses a nested circle diagram to visualize the funnel of patients from total prevalence to treatment non-responders.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
12
The slide uses a table to establish clinical credibility for the MM-120 program by citing historical and contemporary research.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations 1 hit
13
The slide presents clinical trial data (STAI-G scores) over 24 weeks, highlighting significant symptom reduction and safety profile.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations Beat · Traction1 hit
14
The slide uses a timeline-based diagram to illustrate the clinical trial protocol.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations Beat · Traction1 hit
16
The slide uses a timeline to map specific digital product categories to clinical development stages.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations 1 hit
17
The slide uses a process-oriented layout to describe the regulatory and commercialization pathway.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations 1 hit
19
The slide outlines a clinical trial design (MMED007) using a timeline-based visualization.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations 1 hit
22
The slide uses a bar chart to bridge the gap between the problem (no drugs) and the solution (R(-)-MDMA alignment with patient needs).MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations 1 hit
23
The slide uses a bar chart to demonstrate the therapeutic index advantage of the R-enantiomer.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations 1 hit
24
The chart shows improvement in social anxiety at 1 month and 6 months, indicating durability of effect.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations 1 hit
04
Uses authority citation (Forbes) to establish the scale of the problem.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations Beat · ProblemLoop · Logic Chain1 hit
07
The slide uses a Gantt-style chart to visualize clinical trial progress for seven distinct programs.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
09
The slide uses a comparative structure to justify the strategic shift in trial design post-acquisition.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · ComplicationLoop · Cost Of Inaction1 hit
11
The table displays statistical significance (p-values) for multiple clinical endpoints.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · EvidenceLoop · Jobs To Be Done1 hit
18
The slide uses a 'Signal Seeking' framework to justify clinical development decisions based on effect size.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
19
The slide uses a biological pathway diagram to illustrate the mechanism of action of the drug candidate.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
20
The table compares key metrics like EC50, half-life, brain:plasma ratio, selectivity, bioavailability, and molecular weight.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
22
Includes a biological mechanism diagram showing the inhibition of TDP-43 phosphorylation by NMRA-CK1δ.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
23
MVAE stands for Multimodal Variational Autoencoder.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
24
The slide uses a biological pathway diagram to illustrate the mechanism of action of the drug candidate.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
25
Includes a detailed biological pathway diagram illustrating the mechanism of action.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
18
The slide uses a high-contrast visual style with a digital circuit-board texture inside the text.Orthofix | Investor Presentation Deck | 22 slides · Orthofix
Pitch deck Investor relations Beat · Financials1 hit
20
Includes detailed breakdown of adjustments for Q2 2022 and Q2 2023.Orthofix | Investor Presentation Deck | 22 slides · Orthofix
Pitch deck Investor relations Beat · Financials1 hit